364-365 / 1173
ESTRO
EORTC 22791; Horiot et al.,
Radiother. Oncol.
25: 231-241, 1992
Oropharyngeal Ca T2-3, N0-1
EORTC Hyperfractionation trial in oropharynx cancer (N = 356)
80.5 Gy - 70 fx - 7 wks vs 70 Gy - 35-40 fx - 7-8 wks
|
|
364-365 / 1173
ESTRO
EORTC 22791; Horiot et al.,
Radiother. Oncol.
25: 231-241, 1992
Oropharyngeal Ca T2-3, N0-1
EORTC Hyperfractionation trial in oropharynx cancer (N = 356)
80.5 Gy - 70 fx - 7 wks vs 70 Gy - 35-40 fx - 7-8 wks